Harmony Biosciences Holdings (HRMY) Earnings Date & Reports

Key Takeaways

• Harmony Biosciences reported third-quarter 2026 WAKIX net revenue of $268.9 million, up 12% year over year but slightly below consensus estimates.
• GAAP (Generally Accepted Accounting Principles) diluted EPS (earnings per share) came in at $0.81, down from $0.87 a year ago and below the consensus of roughly $1.10.
• Cost of product sold climbed to 30% of net revenue, up from 25% a year earlier, driven by new royalty obligations that pressured gross margins.
• Demand remained healthy, with the average number of patients on WAKIX rising by about 400 to 9,350 during the quarter.
• Management reiterated full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.
• Preliminary multiple-ascending dose (MAD) data for the BP-205 orexin-2 receptor agonist reinforced a favorable safety and tolerability profile.
• For more detail on Harmony Biosciences, visit the company's Major News and Today's Price Move pages, review Price Targets, and explore the Forecast page for additional data and analysis.
• Discover actionable trading ideas and automated strategies by exploring Trending AI Robots.

Earnings Context and Why It Matters

Harmony Biosciences is a commercial-stage pharmaceutical company built around WAKIX (pitolisant), the only non-scheduled treatment approved for excessive daytime sleepiness and cataplexy in adult and pediatric patients with narcolepsy. The third quarter matters because it tests whether the company can sustain top-line growth while absorbing structurally higher royalty costs tied to its licensing agreements. Heading into the print, investors were also watching the BP-205 pipeline program and a planned CEO transition to Peter Anastasiou effective January 1, 2027. The results highlight a franchise that continues to grow, even as the economics of each additional revenue dollar have become less favorable.

Reported Results

For the third quarter ended September 30, 2026, Harmony Biosciences reported WAKIX net revenue of $268.9 million, a 12% increase from $239.5 million in the prior-year period. The figure came in modestly below consensus estimates of roughly $273 million to $275 million. Net income was $48.2 million, or $0.81 per diluted share, compared with $50.9 million, or $0.87 per diluted share, a year earlier. Diluted EPS fell short of the consensus expectation of approximately $1.10.

The earnings shortfall was driven primarily by costs rather than demand. Cost of product sold rose to $80.7 million, or 30% of net revenue, up from $59.7 million, or 25%, a year ago, reflecting new royalties under the Novitium license agreement. A milestone charge tied to the MSN license also lifted research and development expenses. On the demand side, the average number of patients on WAKIX increased by roughly 400 to about 9,350, and management reiterated full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Harmony Biosciences and the broader pharmaceutical sector, the AI Screener offers a structured way to identify opportunities aligned with specific technical and fundamental criteria.

Market Reaction and Investor Sentiment

Harmony Biosciences shares traded lower following the report, with the stock down roughly 6% to 7% on the day as investors weighed the EPS and revenue miss against the company's reiterated guidance and pipeline progress. The reaction reflected concern that rising royalty obligations and milestone charges are compressing margins, even as WAKIX demand remains solid. Commentary from the earnings call emphasized that a roughly 30% cost-of-product-sold ratio is expected to be the go-forward run rate, while a pending legal ruling in the ANDA (Abbreviated New Drug Application) litigation and the anticipated launch of a competing orexin agonist added to investor caution.

Forward Outlook and Key Factors to Monitor

The central question for Harmony Biosciences is whether WAKIX can continue funding a maturing pipeline even as royalty costs reshape the income statement. Management has reaffirmed its goal of exceeding $1 billion in net sales in 2026, but the fourth-quarter implied range of roughly $254 million to $294 million leaves limited room for upside relative to the third quarter's result.

Several catalysts will shape the narrative over the coming quarters. The FDA (U.S. Food and Drug Administration) has set a PDUFA (Prescription Drug User Fee Act) date of April 1, 2027, for the pitolisant GR (gastro-resistant) new drug application, with a potential launch in the first half of 2027. Phase 3 topline data for pitolisant HD is expected in 2027.

On the pipeline front, investors will watch for Phase 1b data for BP-205 in sleep-deprived healthy volunteers, expected in the first quarter of 2027, followed by planned Phase 2 studies across multiple CNS (central nervous system) indications by mid-2027. The February 2027 patent ruling in the ANDA litigation also represents a meaningful near-term event for WAKIX exclusivity. Finally, the January 1, 2027, transition to new CEO Peter Anastasiou could influence strategic direction, including the company's stated appetite for business development.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations